
Free Daily Podcast Summary
by Timmerman Report
"The Long Run"Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
The most recent episodes — sign up to get AI-powered summaries of each one.
Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.
Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.
Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.
Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
"The Long Run"Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from The Long Run with Luke Timmerman in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of The Long Run with Luke Timmerman as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Timmerman Report.
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
The Long Run with Luke Timmerman publishes biweekly. Our AI generates a summary within hours of each new episode.
The Long Run with Luke Timmerman covers topics including Science. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.